1 min read 
 
 
 BridgeBio to stop development of therapy for genetic disorder
 
 It will reduce its gene therapy development budget by more than $50 million, and seek partnership opportunities to support future development of the therapy, BBP-631, or newer treatments for congenital adrenal hyperplasia (CAH).. Updated On Sep 11, 2024 at 10:50 PM IST
 
 
 
 
 
 
 
 
 
 
 
 
 London: BridgeBio Pharma said on Tuesday it will stop development of its disease that .. The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to .. It will reduce its by more than $50 million, and seek partnership of the therapy, BBP-631, or newer (CAH).. caused by a mutation in an enzyme needed to produce cortisol, which is secreted by the adrenal gland.. Advt
 
 
 
 
 
 The study showed that production of cortisol in all patients.. Cortisol helps the body to respond to injury, stress or illness.. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli) 
 
 
 
 
 
 
 Published On Sep 11, 2024 at 10:45 PM IST
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Be the first one to comment.. COMMENTS
 
 
 
 
 
 
 
 
 
 
 
 
 All Comments 
 
 
 
 By commenting, you agree to the 
 
 
 
 
 By commenting, you agree to the 
 
 
 
 
 Find this Comment Offensive?
 Choose your reason below and click on the submit button.. This will alert our moderators to take actions
 
 REASONS FOR REPORTING
 
 
 
 Foul Language
 
 
 
 Defamatory
 
 
 
 Inciting hatred against a certain community
 
 
 
 Out of Context / Spam
 
 
 
 Others 
 
 
 
 
 
 
 Report
 
 
 
 
 
 
 
 
 
 
 
 
 Join the community of 2M+ industry professionals 
 Subscribe to our newsletter to get latest insights & analysis.